Search the GHTC website

Global health R&D delivers for Oklahoma

US government investment in global health R&D has delivered

Amount
$31.2 million
to Oklahoma research institutions
Jobs
450+ new jobs
for Oklahoma
Oklahoma's top USG-funded global health R&D institutions

Oklahoma's top USG-funded global health R&D institutions

University of Oklahoma
$17.8 million
Oklahoma State University
$10.1 million
The Oklahoma Medical Research Foundation (OMRF)
$1.7 million
IMMY (previously Immuno-Mycologics Inc.)
$732 thousand
Cherokee Nation
$336 thousand
Northbound Therapeutics*
$278 thousand
Bijhem Scientific Inc.
$191 thousand

Oklahoma's top areas of global health R&D by USG funding

11.5%
COVID-19
10.3%
Diarrheal diseases
1.2%
Flioviral diseases (including Ebola, Marburg)
6.5%
HIV/AIDS
10.1%
Malaria
25.5%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
6.5%
Reproductive health
7.5%
Salmonella infections
8.9%
Tuberculosis
4.5%
Zika
7.4%
Multi-disease/health area R&D
Global health R&D at work in Oklahoma

Researchers at the University of Oklahoma are studying how, at a molecular level, coronaviruses replicate and cause disease. Using state-of-the-art CRISPR genome editing techniques and reverse genetics, which involves modifying gene sequences, researchers are pinpointing vulnerabilities or targets where it might be possible to inhibit viral activity. These findings could inform antiviral drug and vaccine development. Coronaviruses are a family of respiratory viruses that not only includes SARS-CoV-2, the virus that causes COVID-19, but also the viruses responsible for other severe diseases with pandemic potential, including Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS).

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID/NIH